Drug Product Lanashield Skin Barrier Recalled Due to Manufacturing Deviations
Blossom Pharmaceuticals recalls 9,600 containers of Lanashield Skin Barrier nationwide due to manufacturing quality deviations. Voluntary recall; no illnesses reported.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: FDA Class II voluntary recall with no reported illnesses or injuries. Meets the rubric criterion for Moderate severity: 'voluntary precautionary recalls' where theoretical risk exists but no adverse health effects have been documented.
Plain-English summary
Blossom Pharmaceuticals is voluntarily recalling 9,600 containers of Lanashield Skin Barrier, a 4 oz. (113 g) topical skin care product, due to current Good Manufacturing Practice (cGMP) deviations. The affected product was distributed nationwide throughout the United States.
Affected lot numbers are: Lot #A162301 (expiration 9/26), Lot #A162401 (expiration 4/27), and Lot #A162202 (expiration 11/25). The product is manufactured in India for Dynarex Corporation and carries UPC 616784126319.
Consumers who have purchased this product should stop using it. No illnesses or injuries have been reported to date. For return or disposal instructions, contact Blossom Pharmaceuticals.
The recalled product
- Product
- Lanashield Skin Barrier, 4 oz. (113 g), Manfuactured for: Dynarex Corporation, 10 Gleshaw Street, Orangeburg, NY 10962 USA, Made in India, UPC 616784126319.
- Manufacturer
- Blossom Pharmaceuticals
- Category
- Drug — Topical / Skin Care
- Hazard
- manufacturing-deviation
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (5)
- Lot #: A162301
- Exp. Date 9/26
- A162401
- Exp. Date 4/27 & A162202
- Exp. Date 11/25.
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27